GNTA Valuation

Genenta Science SPA

Add to Watchlist

Advanced Chart

2.180

-0.04(-1.802%)1D

GNTA Relative Valuation

GNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GNTA is overvalued; if below, it's undervalued.

Historical Valuation

Genenta Science SPA (GNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 1.87 is considered Fairly compared with the five-year average of -8.96. The fair price of Genenta Science SPA (GNTA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.18

Fair

-2.57

Trailing

Forward

0.00

EV/EBITDA

Genenta Science SPA. (GNTA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -5.13. The thresholds are as follows: Strongly Undervalued below -15.64, Undervalued between -15.64 and -10.39, Fairly Valued between 0.12 and -10.39, Overvalued between 0.12 and 5.38, and Strongly Overvalued above 5.38. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.72

EV/EBIT

Genenta Science SPA. (GNTA) has a current EV/EBIT of -1.72. The 5-year average EV/EBIT is -5.39. The thresholds are as follows: Strongly Undervalued below -12.57, Undervalued between -12.57 and -8.98, Fairly Valued between -1.80 and -8.98, Overvalued between -1.80 and 1.80, and Strongly Overvalued above 1.80. The current Forward EV/EBIT of -1.72 falls within the Overvalued range.

1.87

Genenta Science SPA. (GNTA) has a current PS of 1.87. The 5-year average PS is 26.94. The thresholds are as follows: Strongly Undervalued below -93.88, Undervalued between -93.88 and -33.47, Fairly Valued between 87.35 and -33.47, Overvalued between 87.35 and 147.76, and Strongly Overvalued above 147.76. The current Forward PS of 1.87 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Genenta Science SPA. (GNTA) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Genenta Science SPA. (GNTA) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.32. The thresholds are as follows: Strongly Undervalued below -11.94, Undervalued between -11.94 and -7.63, Fairly Valued between 0.99 and -7.63, Overvalued between 0.99 and 5.30, and Strongly Overvalued above 5.30. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Genenta Science SPA (GNTA) has a current Price-to-Book (P/B) ratio of 2.96. Compared to its 3-year average P/B ratio of 3.90 , the current P/B ratio is approximately -24.13% higher. Relative to its 5-year average P/B ratio of 3.73, the current P/B ratio is about -20.69% higher. Genenta Science SPA (GNTA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -11.97%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -10.37% , the current FCF yield is about -100.00% lower.

2.96

P/B

Median3y

3.90

Median5y

3.73

-25.49

FCF Yield

Median3y

-11.97

Median5y

-10.37

Competitors Valuation Multiple

The average P/S ratio for GNTA's competitors is 3.95, providing a benchmark for relative valuation. Genenta Science SPA Corp (GNTA) exhibits a P/S ratio of 1.87, which is -52.63% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Aligos Therapeutics Inc

Barinthus Biotherapeutics PLC

PDS Biotechnology Corp

0.96

39.41M

Performance Decomposition

Market capitalization of GNTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GNTA in the past 1 year is driven by Unknown.